Item 7.01 Regulation FD Disclosure.

On December 28, 2020, Cara Therapeutics, Inc. (the "Company") issued a press release announcing the submission of the new drug application to the U.S. Food and Drug Administration for KORSUVA™ Injection for the treatment of moderate-to-severe pruritus in hemodialysis patients. The information furnished under this Item 7.01, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or subject to the liabilities of that section. The information shall not be deemed incorporated by reference into any other filing with the Securities and Exchange Commission made by the Company, regardless of any general incorporation language in such filing.

Item 9.01 Financial Statements and Exhibits.






(d) Exhibits



Exhibit
No.        Description

  99.1       Press release dated December 28, 2020
104        Cover Page Interactive Data File (embedded within the Inline XBRL document).

© Edgar Online, source Glimpses